

www.georgianradiology.com

BONE MINERAL DENSITY (DEXA)

☐ Wasaga - 14 Ramblewood Dr. Suite 105

705-422-2255

☐ Barrie - 11 Lakeside Terrace, Suite LL01

705-722-8036

BOOKING PHONE # : / U5- / 20 - / 442	BOOKING FAX#:/US	- /20- 8030
PATIENT Appointment: Booked appt only		
Date: D M Y	Time:	am / pm
PREPARATION: If you have had a Nuclear Medicine, CT scan with contrast or Ba Dress in comfortable clothing without metal: no belts, zippers or bra and no na		
	verjeweny. This will eliminate the need to en	ange into a gown.
Baseline (1st ever in Ontario)		
Patients with any of the following risk factors (check ALL	that apply):	
☐ Female or Male age≥65	■ Menopausal female (≥1 year post cessation of	
☐ History of fragility fracture (after age 40)	menstrual periods) with body weight < 60kg	
 Recent prolonged glucocorticoid use² Other high risk medication use³ 	☐ Male age 50–64 with body	weight < 60 kg
 Other high risk medication use³ Conditions associated with bone loss or fracture⁴ SPE 	FCIFY:	
Low Risk Follow Up	PLEASE ATTACH PREVIO	DUS REPORT
For patients at LOW fracture risk on prior exam, OHIP will co	over:	
☐ A second BMD test 3 YEARS AFTER the baseline test		
☐ A successive BMD test (i.e. 3 rd or more) 5 YEARS AFTER the last test		
Date Last Exam (Day Month Year	_	
Follow up BMD tests at intervals of EVERY 2-3 YEARS are appropriate for most MODE	RATE or HIGH risk patients (including those rec	
High Risk Follow Up		Comments:
☐ 2-3 year follow up with previous Moderate to High Risk B	MD without changes to risk level	
☐ 1 year follow up		
-for any patient, follow up BMD Tests may be appropriate	AFTER 1 YEAR if:	
Has a new fragility fracture ¹		
☐ Active risk factor for bone loss ^{2,3,4}		
☐ Significant bone loss on prior BMD exam ⁶		
Initiated or changed to a new bone sparing medicat	ion within the past year	REV. Mar2018
defined as fracture that occurs spontaneously such as vertebral fracture identific EXCLUDING craniofacial, hand, ankle, foot and rib fractures	ed on X-ray or after minor trauma such as a fall fror	n standing height or less,
2 ≥3 months in the prior year at a prednisone equivalent dose ≥ 7.5 mg daily		
³ e.g. aromatase inhibitors, androgen deprivation therapy, anticonvulsant therap	y	
⁴ e.g. primary hyperparathyroidism, osteogenesis imperfecta, uncontrolled hyper or malabsorption syndrome, chronic liver disease and inflammatory conditions	(e.g. inflammatoryolovel disease, lupus, rheum	atoid arthritis)
⁵ refer to 2014 Choosing Wisely Canada recommendations: http://www.choosing ⁶ OHIP defines significant bone loss as being in excess of 1% per year	gwisely canada.org/recommendations/rheum	atology/
PATIENT INFORMATION:	TECH NOTI	
	□NCP	
DATE: DMYM / F DOB: DMY		
Name:	Practitioner SIGNA	ATURE:
Address: City:		: Signature
Home P#: Cell P#:		: Printed Name
Province: OHIP# / WCB#:		: CC Copy